Key Takeaways
- David Wells, a board member, acquired 48,400 shares of HIMS for approximately $1.2 million — marking his initial open-market transaction in close to five years.
- Following the disclosure, HIMS stock climbed roughly 6.8% to reach $25.46.
- Year-to-date, HIMS has declined over 21% in 2026, trailing the S&P 500’s 9.9% increase.
- Shares fell more than 14% in early May following disappointing first-quarter earnings.
- The company is transitioning away from compounded GLP-1 medications as Novo Nordisk and Eli Lilly restore their market dominance.
David Wells, a board member at Hims & Hers Health (HIMS), acquired 48,400 shares this Tuesday, paying between $24.19 and $24.25 per share for a combined investment of approximately $1.2 million. This transaction increased his holdings to 224,400 shares and represented his first purchase on the open market since August 2021.
Hims & Hers Health, Inc., HIMS
The announcement created immediate market impact. HIMS stock surged approximately 6.8% to $25.46 on the trading day following the filing, with market participants interpreting the insider purchase as a strong signal of confidence.
Wells, who previously held the position of CFO at Netflix and joined the Hims board in 2020, had been exclusively selling shares in recent years — disposing of 260,000 shares during February 2024 and an additional 40,000 in November of that year. His switch to purchasing after nearly half a decade of sales captured significant attention from market observers.
Understanding HIMS’s 2026 Challenges
Shares of HIMS have tumbled more than 21% year-to-date, substantially underperforming the S&P 500’s 9.9% advance during the same timeframe. This performance divergence highlights the company’s current struggles.
Earlier this May, the stock experienced a sharp decline exceeding 14% following the release of first-quarter results that fell short of analyst projections. The telehealth company reported a quarterly loss alongside revenue figures that disappointed Wall Street — outcomes that frustrated shareholders.
A more significant worry for the investment community centers on the company’s GLP-1 medication segment. When shortages affected branded weight-loss treatments from Novo Nordisk and Eli Lilly, Hims experienced rapid expansion by providing more affordable compounded alternatives. However, with supply constraints now resolved, Novo and Lilly have begun recapturing their lost market position.
Strategic Shift From Compounded Alternatives
This March, Hims announced an agreement to distribute Novo’s branded weight-loss drugs directly via its digital platform, substituting the compounded options it had previously marketed. The following month, the company expanded its platform functionality to enable healthcare providers to issue prescriptions that can be filled through independent pharmacies, including LillyDirect.
This represents a significant strategic transformation. Compounded GLP-1 treatments had evolved into a fundamental component of how Hims differentiated itself in the marketplace and attracted investor interest. Maintaining revenue momentum while transitioning away from these products represents the company’s current primary obstacle.
Separately, Wells was granted 957 restricted stock units on May 20, consistent with routine equity compensation for directors.
As of Wednesday’s market close, HIMS shares were priced at $25.46, reflecting a 6.8% gain for the session when the purchase was disclosed.
